DeepLife
Created in 2019
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
44 3,399Activities
Technologies
Entity types
Location
75013 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 28
Engaged catalyst
21
0 0Added in Motherbase
4 years, 1 month ago
Value proposition
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
Drug Discovery, Pharmaceutical, Deep Learning, and BiotechOriginal language
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
DeepLife | Digital Twin of Cells for Drug Discovery
At DeepLife, we harness deep learning on multi-omics data to model cells and efficiently engineer their behavior
https://www.deeplife.co/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 28 Nov 2024 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 28 Nov 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 11 Mar 2025 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 11 Dec 2024 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 21 Jun 2024 | | |
 Orange Telecoms, Law Practice, Telecommunications | Orange Telecoms, Law Practice, Telecommunications | Other 11 Mar 2025 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 23 Aug 2023 | | |
 France Digitale Startup accelerator & VC, Non-profit Organizations | France Digitale Startup accelerator & VC, Non-profit Organizations | Other 13 Feb 2025 | | |
 Avolta Finance, Investment Banking | Avolta Finance, Investment Banking | Other 15 Dec 2024 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 8 Jul 2020 | | |